Bank of New York Mellon’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.34M | Buy |
224,176
+33,777
| +18% | +$1.09M | ﹤0.01% | 2127 |
|
|
2026
Q1 | $6.04M | Sell |
190,399
-4,153
| -2% | -$113K | ﹤0.01% | 2208 |
|
|
2025
Q4 | $5.28M | Sell |
194,552
-11,142
| -5% | -$293K | ﹤0.01% | 2292 |
|
|
2025
Q3 | $5.32M | Buy |
205,694
+11,593
| +6% | +$269K | ﹤0.01% | 2275 |
|
|
2025
Q2 | $3.95M | Buy |
194,101
+20,215
| +12% | +$393K | ﹤0.01% | 2404 |
|
|
2025
Q1 | $3.16M | Sell |
173,886
-7,724
| -4% | -$173K | ﹤0.01% | 2447 |
|
|
2024
Q4 | $4.59M | Buy |
181,610
+410
| +0.2% | +$11.1K | ﹤0.01% | 2341 |
|
|
2024
Q3 | $6.16M | Sell |
181,200
-48,962
| -21% | -$1.87M | ﹤0.01% | 2188 |
|
|
2024
Q2 | $8.52M | Buy |
230,162
+29,324
| +15% | +$1.11M | ﹤0.01% | 2046 |
|
|
2024
Q1 | $8.43M | Buy |
200,838
+31,699
| +19% | +$1.3M | ﹤0.01% | 2042 |
|
|
2023
Q4 | $6.71M | Buy |
169,139
+4,982
| +3% | +$147K | ﹤0.01% | 2220 |
|
|
2023
Q3 | $4.52M | Buy |
164,157
+2,408
| +1% | +$75.5K | ﹤0.01% | 2367 |
|
|
2023
Q2 | $5.49M | Sell |
161,749
-3,319
| -2% | -$112K | ﹤0.01% | 2274 |
|
|
2023
Q1 | $5.94M | Sell |
165,068
-3,921
| -2% | -$169K | ﹤0.01% | 2204 |
|
|
2022
Q4 | $7.53M | Buy |
168,989
+6,207
| +4% | +$222K | ﹤0.01% | 2098 |
|
|
2022
Q3 | $4.58M | Buy |
162,782
+13,197
| +9% | +$405K | ﹤0.01% | 2332 |
|
|
2022
Q2 | $4.03M | Sell |
149,585
-4,118
| -3% | -$120K | ﹤0.01% | 2432 |
|
|
2022
Q1 | $5.24M | Buy |
153,703
+243
| +0.2% | +$7.77K | ﹤0.01% | 2397 |
|
|
2021
Q4 | $5.93M | Sell |
153,460
-19,286
| -11% | -$840K | ﹤0.01% | 2372 |
|
|
2021
Q3 | $9.33M | Buy |
172,746
+56,311
| +48% | +$2.64M | ﹤0.01% | 2158 |
|
|
2021
Q2 | $3.89M | Buy |
116,435
+67,182
| +136% | +$1.84M | ﹤0.01% | 2612 |
|
|
2021
Q1 | $1.01M | Sell |
49,253
-2,285
| -4% | -$52.5K | ﹤0.01% | 3321 |
|
|
2020
Q4 | $903K | Buy |
51,538
+32,689
| +173% | +$588K | ﹤0.01% | 3311 |
|
|
2020
Q3 | $280K | Buy |
+18,849
| New | +$221K | ﹤0.01% | 3745 |
|
|
2019
Q2 | – | Sell |
-25,521
| Closed | -$126K | – | 4222 |
|
|
2019
Q1 | $126K | Buy |
25,521
+19,799
| +346% | +$104K | ﹤0.01% | 3967 |
|
|
2018
Q4 | $17K | Sell |
5,722
-20
| -0.3% | -$98 | ﹤0.01% | 4171 |
|
|
2018
Q3 | $39K | Buy |
5,742
+20
| +0.3% | +$140 | ﹤0.01% | 4152 |
|
|
2018
Q2 | $43K | Sell |
5,722
-38,295
| -87% | -$512K | ﹤0.01% | 4112 |
|
|
2018
Q1 | $1.54M | Sell |
44,017
-2,025
| -4% | -$78.5K | ﹤0.01% | 2964 |
|
|
2017
Q4 | $1.96M | Buy |
46,042
+4,547
| +11% | +$195K | ﹤0.01% | 2850 |
|
|
2017
Q3 | $1.78M | Buy |
41,495
+1,460
| +4% | +$54.7K | ﹤0.01% | 2901 |
|
|
2017
Q2 | $1.48M | Buy |
40,035
+4,158
| +12% | +$184K | ﹤0.01% | 3021 |
|
|
2017
Q1 | $1.94M | Buy |
35,877
+374
| +1% | +$19.5K | ﹤0.01% | 2871 |
|
|
2016
Q4 | $1.89M | Buy |
35,503
+6,905
| +24% | +$393K | ﹤0.01% | 2887 |
|
|
2016
Q3 | $1.73M | Sell |
28,598
-1,451
| -5% | -$90.4K | ﹤0.01% | 2846 |
|
|
2016
Q2 | $1.98M | Sell |
30,049
-1,100
| -4% | -$69.8K | ﹤0.01% | 2713 |
|
|
2016
Q1 | $1.77M | Sell |
31,149
-50
| -0.2% | -$5.63K | ﹤0.01% | 2730 |
|
|
2015
Q4 | $7.34M | Buy |
31,199
+250
| +0.8% | +$54.5K | ﹤0.01% | 2001 |
|
|
2015
Q3 | $4.89M | Sell |
30,949
-74,810
| -71% | -$21.2M | ﹤0.01% | 2246 |
|
|
2015
Q2 | $40M | Buy |
105,759
+4,764
| +5% | +$1.89M | 0.01% | 1035 |
|
|
2015
Q1 | $42.2M | Sell |
100,995
-65,809
| -39% | -$23.5M | 0.01% | 1001 |
|
|
2014
Q4 | $45.7M | Buy |
166,804
+13,393
| +9% | +$3.33M | 0.01% | 939 |
|
|
2014
Q3 | $29.8M | Buy |
153,411
+1,458
| +1% | +$318K | 0.01% | 1172 |
|
|
2014
Q2 | $37.2M | Buy |
151,953
+121,290
| +396% | +$27.4M | 0.01% | 1072 |
|
|
2014
Q1 | $8.13M | Sell |
30,663
-3,205
| -9% | -$1.23M | ﹤0.01% | 2030 |
|
|
2013
Q4 | $12.3M | Buy |
33,868
+1,910
| +6% | +$736K | ﹤0.01% | 1754 |
|
|
2013
Q3 | $17M | Buy |
31,958
+3,338
| +12% | +$1.14M | 0.01% | 1504 |
|
|
2013
Q2 | $6.7M | Buy |
+28,620
| New | +$5.64M | ﹤0.01% | 2023 |
|
Other funds holding CLDX
PAM
TCMG
MCP
Bank of New York Mellon's CLDX Position: Q2 2026 in Review
Bank of New York Mellon increased its Celldex Therapeutics (CLDX) stake by 18% in Q2 2026, buying an estimated $1.09M and bringing the position to 224,176 shares worth $8.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2127.
Bank of New York Mellon first reported a position in CLDX in Q2 2013 and has held it in 48 quarters since. The position peaked at $45.7M in Q4 2014. 78 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.
- Bank of New York Mellon held 224,176 shares of Celldex Therapeutics worth $8.34M as of Q2 2026.
- Bank of New York Mellon bought 33,777 Celldex Therapeutics shares in Q2 2026, an estimated $1.09M.
- Celldex Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2127 holding.
- Bank of New York Mellon first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 48 quarters since.
- Bank of New York Mellon's Celldex Therapeutics position peaked at $45.7M in Q4 2014.
- 78 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.